The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Tango Therapeutics Inc (NASDAQ: TNGX) closed at $6.88 up 1.78% from its previous closing price of $6.76. In other words, the price has increased by $1.78 from its previous closing price. On the day, 1.24 million shares were traded. TNGX stock price reached its highest trading level at $7.15 during the session, while it also had its lowest trading level at $6.6.
Ratios:
For a deeper understanding of Tango Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.75 and its Current Ratio is at 4.75. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on July 17, 2024, initiated with a Buy rating and assigned the stock a target price of $19.
On February 12, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $18.Piper Sandler initiated its Overweight rating on February 12, 2024, with a $18 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 04 ’25 when Barry Douglas sold 2,774 shares for $2.99 per share. The transaction valued at 8,289 led to the insider holds 68,570 shares of the business.
Barry Douglas sold 2,556 shares of TNGX for $8,081 on Feb 05 ’25. The General Counsel now owns 66,014 shares after completing the transaction at $3.16 per share. On Feb 04 ’25, another insider, Beckman Daniella, who serves as the Chief Financial Officer of the company, sold 4,284 shares for $2.99 each. As a result, the insider received 12,801 and left with 154,232 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNGX now has a Market Capitalization of 765468800 and an Enterprise Value of 619693504. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.50 while its Price-to-Book (P/B) ratio in mrq is 5.65. Its current Enterprise Value per Revenue stands at 25.506 whereas that against EBITDA is -4.003.
Stock Price History:
The Beta on a monthly basis for TNGX is 1.64, which has changed by -0.26808512 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, TNGX has reached a high of $12.02, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 20.79%, while the 200-Day Moving Average is calculated to be 103.18%.
Shares Statistics:
For the past three months, TNGX has traded an average of 3.23M shares per day and 2170710 over the past ten days. A total of 110.87M shares are outstanding, with a floating share count of 61.84M. Insiders hold about 44.42% of the company’s shares, while institutions hold 63.93% stake in the company. Shares short for TNGX as of 1753920000 were 22475890 with a Short Ratio of 6.95, compared to 1751241600 on 21193333. Therefore, it implies a Short% of Shares Outstanding of 22475890 and a Short% of Float of 24.239999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Tango Therapeutics Inc (TNGX) is currently being evaluated by a team of 8.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.25 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$0.95 and -$1.49 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is -$1.42, with 7.0 analysts recommending between -$1.1 and -$1.83.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $39.57M this quarter.It ranges from a high estimate of $53.81M to a low estimate of $3.18M. As of the current estimate, Tango Therapeutics Inc’s year-ago sales were $11.61M
A total of 7 analysts have provided revenue estimates for TNGX’s current fiscal year. The highest revenue estimate was $62.4M, while the lowest revenue estimate was $14.94M, resulting in an average revenue estimate of $52.71M. In the same quarter a year ago, actual revenue was $42.07M
